March Biosciences
- Biotech or pharma, therapeutic R&D
Cell therapy company with a best and first in class asset (MB-105) currently in a multi-center Phase 2 study for T cell lymphoma (TCL), a $3B US annual market with limited targeted treatment options and exceptionally poor prognoses. Lead asset MB-105 has multiple long-term clinical responses.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}